Sivik Global Healthcare LLC Buys Shares of 10,000 Ascendis Pharma A/S (NASDAQ:ASND)

Sivik Global Healthcare LLC acquired a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $1,493,000.

A number of other large investors have also made changes to their positions in ASND. Price T Rowe Associates Inc. MD grew its holdings in Ascendis Pharma A/S by 23.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock worth $269,374,000 after acquiring an additional 336,976 shares in the last quarter. Acadian Asset Management LLC grew its holdings in shares of Ascendis Pharma A/S by 1,461.1% in the 1st quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company’s stock worth $37,849,000 after acquiring an additional 234,446 shares during the last quarter. Avoro Capital Advisors LLC grew its position in Ascendis Pharma A/S by 5.8% during the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock worth $572,341,000 after purchasing an additional 229,995 shares in the last quarter. Fred Alger Management LLC increased its holdings in shares of Ascendis Pharma A/S by 65.0% in the 2nd quarter. Fred Alger Management LLC now owns 307,073 shares of the biotechnology company’s stock valued at $41,879,000 after purchasing an additional 120,952 shares during the period. Finally, Tri Locum Partners LP boosted its stake in shares of Ascendis Pharma A/S by 102.1% during the 2nd quarter. Tri Locum Partners LP now owns 227,762 shares of the biotechnology company’s stock valued at $31,062,000 after buying an additional 115,092 shares during the period.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. StockNews.com cut Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research report on Tuesday. Evercore ISI lifted their price target on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an “outperform” rating in a report on Tuesday, September 17th. TD Cowen increased their target price on Ascendis Pharma A/S from $157.00 to $160.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Oppenheimer reaffirmed an “outperform” rating and issued a $190.00 price target (up from $180.00) on shares of Ascendis Pharma A/S in a research note on Tuesday, September 17th. Finally, Wedbush raised Ascendis Pharma A/S to a “strong-buy” rating in a research note on Monday, November 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Ascendis Pharma A/S has a consensus rating of “Moderate Buy” and a consensus target price of $195.92.

Ascendis Pharma A/S Stock Performance

Shares of ASND stock traded down $0.15 during mid-day trading on Thursday, reaching $125.88. 15,384 shares of the company’s stock traded hands, compared to its average volume of 441,269. Ascendis Pharma A/S has a 12 month low of $90.13 and a 12 month high of $161.00. The firm has a market capitalization of $7.63 billion, a PE ratio of -13.54 and a beta of 0.66. The firm has a 50 day moving average price of $132.04 and a two-hundred day moving average price of $132.86.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The company had revenue of $38.75 million during the quarter, compared to the consensus estimate of $94.74 million. As a group, equities analysts expect that Ascendis Pharma A/S will post -7.35 earnings per share for the current fiscal year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.